Rubius Therapeutics rubiustx.com


Public list: Pharma Startups (4733) Cancer Therapeutics (1135)

Rubius Therapeutics is developing Red-Cell Therapeutics (RCTs) as a new treatment modality to address a wide array of indications including cancer, autoimmune disease, rare disease and metabolic disease. RCTs are enucleated cell-based therapies that can be engineered to have diverse activities. The company has established a platform for the rapid design, generation, testing and development of RCT products.

Rubius Therapeutics is developing Red-Cell Therapeutics (RCTs) as a new treatment modality to address a wide array of indications including cancer, autoimmune disease, rare disease and metabolic disease. RCTs are enucleated cell-based therapies that ...Show all

Company (Alive / Active)

Phone: 617-679-9600

Fax:

325 Vassar Street
Suite 1A
Cambridge, 02139
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Rubius Therapeutics $245M Mar 1, 2018

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Rubius Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Synthetic membrane-receiver complexes Jun 12, 2015 May 09, 2017 Patent
Synthetic membrane-receiver complexes Nov 28, 2017 Application
Synthetic membrane-receiver complexes Oct 13, 2017 Application
Compositions and methods related to multimodal therapeutic cell systems for cancer indications Sep 26, 2017 Application
Synthetic membrane-receiver complexes Mar 29, 2017 Application
See all 8 patents